German Health Minister Jens Spahn has announced the first clinical trials of a coronavirus vaccine. The Paul Ehrlich Institute (PEI), the regulatory authority which helps develop and authorizes vaccines in Germany, has given the go-ahead for the first clinical trial of BNT162b1, a vaccine against the SARS-CoV-2 virus.
It was developed by cancer researcher and immunologist Ugur Sahin and his team at pharmaceutical company BioNTech, and is based on their prior research into cancer immunology. Sahin previously taught at the University of Mainz before becoming the CEO of BioNTech.
Numerous vaccines in development
Aside from BNT162b1, which is now in the stage 1 testing phase, BioNTech — jointly with Pfizer — is working on three other similar mRNA vaccines. […]
Cichutek said testing would be completed by June, at the earliest. After this stage is complete, the PEI will determine if the vaccine can progress to further trial stages. Cichutek warned, however, that an approved vaccine was unlikely to be ready for the general public in 2020. […]
addendum from µthos:
We start with testing 200 healthy young adults.
If that goes well, next step will be up to age 50.